TLR9 and Sjogren syndrome: More specifically, the beneficial effect of the humanized form of mEN101 in attenuating inflammatory responses in Sjogren's syndrome [20] and in models of posttraumatic anxiety [21] has been attributed to noncanonical activation of NF-κB via activation of Toll-like-receptor 9.